<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190979</url>
  </required_header>
  <id_info>
    <org_study_id>VP-000 214</org_study_id>
    <nct_id>NCT04190979</nct_id>
  </id_info>
  <brief_title>Clinical Application of the Medyria TrackCath System in Endovascular Repair of Abdominal Aortic Aneurysms (AAA)</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>Clinical Application of the Medyria TrackCath System in Endovascular Repair of Abdominal Aortic Aneurysms (AAA) - A Prospective Multi-centre Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medyria AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>StatConsult Gesellschaft für klinische und Versorgungsforschung mbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Axxos GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Mind RCS GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medyria AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-market, single-arm, prospective, open-label, multi-center clinical trial aimed at&#xD;
      assessing the safety and the performance of the Medyria TrackCath system in patients&#xD;
      undergoing endovascular intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-market, single-arm, prospective, open-label, multi-center clinical trial aimed at&#xD;
      assessing the safety and the performance of the Medyria TrackCath system in patients above&#xD;
      the age of 18 years who have been diagnosed with aneurysms in the thoracoabdominal (TAAA) or&#xD;
      abdominal (AAA) aorta and require endovascular intervention.&#xD;
&#xD;
      The TrackCath System is a non-implantable disposable device, intended to measure real-time&#xD;
      changes in the Blood Flow Velocity and to provide a pathway for delivering third-party&#xD;
      guidewires and/or catheters.&#xD;
&#xD;
      Following patient consent, data is collected until discharge.&#xD;
&#xD;
      To reach 80% power, a total number of 32 patients (minimum 42 target orifices) is scheduled,&#xD;
      including a minimum of 8 roll-in patients for the training phase, which comprises at least&#xD;
      two successful cases per center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2018</start_date>
  <completion_date type="Actual">February 25, 2019</completion_date>
  <primary_completion_date type="Actual">February 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Success Rate</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Successful TrackCath delivery of the distal end of the guidewire or of the 4 French catheter to the selected targeted orifice(s).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety (All SADEs)</measure>
    <time_frame>Up to discharge (expected to be within 1 month)</time_frame>
    <description>Occurrence of Serious Adverse Device Effects (SADE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety (All AEs)</measure>
    <time_frame>Up to discharge (expected to be within 1 month)</time_frame>
    <description>All Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Parameters (contrast dye)</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Amount of contrast dye used (ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Parameters (procedural times)</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Exposure time to X-ray (min); total duration of the procedure (min); duration of the target orifice identification and cannulation (min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Parameters (Blood flow velocity)</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Blood flow velocity changes between above orifice and at orifice (m/s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon satisfaction rate</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Surgeon satisfaction on the use of the TrackCath catheter and the Blood Flow Velocity sensor, expressed on a scale from 1 (very bad) to 5 (very good).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <condition>Aortic Aneurysm, Thoracoabdominal</condition>
  <condition>Acute Renal Failure</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>Acute Kidney Failure</condition>
  <condition>Acute Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TrackCath</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medyria TrackCath System</intervention_name>
    <description>The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has signed and understood the approved Informed Consent form and is able to&#xD;
             meet the proposed study proceedings (CIP).&#xD;
&#xD;
          -  Patient is ≥18 years of age&#xD;
&#xD;
          -  Need for standard or complex EVAR of AAA according to the relevant guidelines:&#xD;
&#xD;
          -  Asymptomatic aneurysms with a diameter &gt; 55mm in men and &gt; 50 mm in woman&#xD;
&#xD;
          -  Aneurysm-growth exceeds 10mm/year&#xD;
&#xD;
          -  Patient requires at least one cannulation during which requires at least one&#xD;
             cannulation (e.g. fenestration of endograft, side-branch and/or contralateral leg of&#xD;
             endograft)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is generally contraindicated for EVAR&#xD;
&#xD;
          -  Patient requires an emergency surgery&#xD;
&#xD;
          -  Patient with an increased risk of aneurysm rupture or saccular aneurysm, aneurysm with&#xD;
             isolated wall protuberances or penetrating aortic ulcer&#xD;
&#xD;
          -  Patient with a dissecting acutely ruptured or leaking aneurysm or an acute vascular&#xD;
             injury caused by a trauma&#xD;
&#xD;
          -  Patient with stroke or transient ischemic attack (TIA) within the last 6 months prior&#xD;
             to baseline&#xD;
&#xD;
          -  Patient with myocardial infarction (MI) with the last 3 months prior to baseline&#xD;
&#xD;
          -  Patient with acute or chronic renal failure (including dialysis); Creatinine &gt; 2.00&#xD;
             mg/dl or &gt; 182 µmol/L&#xD;
&#xD;
          -  Patient with co-morbidities that constitutes an unacceptable risk (for example chronic&#xD;
             obstructive pulmonary disease (COPD), liver failure, immunosuppression, polyneuropathy&#xD;
             and hematological diseases)&#xD;
&#xD;
          -  Patient with bleeding history or coagulopathy&#xD;
&#xD;
          -  Patient with contraindication or allergies to take anticoagulants, antiplatelet drugs&#xD;
             or contrast media&#xD;
&#xD;
          -  Life expectancy of less than 5 years&#xD;
&#xD;
          -  Female patient that is pregnant, is planning on becoming pregnant in the next month or&#xD;
             is breastfeeding&#xD;
&#xD;
          -  Patient with inability to obtain vascular access&#xD;
&#xD;
          -  Patient has an active local or systemic infection&#xD;
&#xD;
          -  Patient is currently participating in another investigational study where the&#xD;
             endpoints have not yet been achieved&#xD;
&#xD;
          -  Patient has a mental illness, and/or been diagnosed as clinically depressed or belongs&#xD;
             to a vulnerable population (e.g., prisoner, severe drug abuser, developmentally&#xD;
             disabled) that would compromise the ability to provide informed consent.&#xD;
&#xD;
          -  Patient has an obstructed or inadequate vasculature by means of tortuous anatomy&#xD;
             hindering the TC catheter to reach target orifice(s)&#xD;
&#xD;
          -  Patient has an elevated risk of plaque dislodgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert Schelzig, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich-Heine University, Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich-Heine University Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endovascular aneurysm repair</keyword>
  <keyword>EVAR</keyword>
  <keyword>AAA</keyword>
  <keyword>Cannulation</keyword>
  <keyword>Blood Flow Velocity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

